Just shy of its 1-year anniversary, radiopharmaceuticals platform play RayzeBio bags another megaround

Perhaps they should have called it RaiseBio.

Not even a full year post-launch, RayzeBio’s radiopharmaceuticals platform has hooked yet another $100 million-plus raise, and it appears the company’s next big catch will be a Nasdaq ticker.